Test Volumes
210M
+23% YoY
Total tests processed in FY26; Q4 alone saw 29% YoY growth.
THYROCARETECHNOLOGIES
Information Technology
01 May 2026
Thyrocare Technologies Ltd — Q4 FY26
Thyrocare delivered a strong Q4 FY26 with consolidated revenue of ₹224 crore (+20% YoY) and PAT of ₹48.7 crore (+128% YoY), driven by 21% growth in franchisee business and 23% in partnerships.
✓ Verified against BSE filing
2-Min Summary
Thyrocare delivered a strong Q4 FY26 with consolidated revenue of ₹224 crore (+20% YoY) and PAT of ₹48.7 crore (+128% YoY), driven by 21% growth in franchisee business and 23% in partnerships. Test volumes surged 29% YoY due to aggressive biochemistry pricing, while gross margins expanded 113bps to 74.7% from vendor negotiations. Management guided for mid-to-high teens revenue growth in FY27, with 75% from volume and 25% from mix, and expects EBITDA margins to remain stable around 32-34% as operating leverage is reinvested into specialty expansion (genomics, allergy). Key risk: potential reagent price increases from dollar strength could pressure margins if not passed on.
Key Numbers
Franchise Count
10,800
+500 QoQ
Highest ever active franchises; management targets ~500 net adds per quarter.
Patients Served
19.2M
+15% YoY
FY26 total patients; reflects growing reach across India.
Complaints per Million Tests
3.06
-180bps YoY
Sustained six sigma quality; complaints reduced significantly.
Management Guidance
Mid-to-high teens revenue growth in FY27
Management expects revenue growth of mid-to-high teens, driven primarily by volume (75%) and mix (25%), with no price increases planned.
revenueStable EBITDA margins around 32-34% in FY27
Normalized EBITDA margin expected to remain stable at ~34% as operating leverage is reinvested into growth initiatives.
marginsFranchise additions of ~500 per quarter
Management targets adding approximately 500 net new franchises each quarter, consistent with current run rate.
growthSpecialty mix to reach 15-20% in 3 years
Management aims to increase specialty testing (genomics, allergy) to 15-20% of revenue within three years, from a low base.
ai_strategyKey Risks
Reagent price increases from dollar strength
Vendors have requested price increases due to dollar appreciation; if sustained, margins could be pressured unless passed on.
medium · analyst_questionPartnership business growth dip due to one-off normalization
Q4 partnership growth slowed to 23% due to normalization of insurance pricing and lower camp volumes; management attributes it to a one-off but it may recur.
low · management_commentaryTanzania business still loss-making
Tanzania operations have not yet broken even after 18 months, with quarterly losses of ~₹1 crore, though minimal.
low · analyst_questionSpecialty expansion may pressure near-term margins
Investments in specialty (genomics, allergy) will have lower gross margins initially, potentially weighing on overall profitability until scale is achieved.
medium · data_observationNotable Quotes
We have no intention at this point in time to increase prices.
Our strategy remains to be the most affordable good quality diagnostic testing partner for anyone in the healthcare business.
Any operating leverage that comes out of the business is what we invest in growth.